Quantcast
Last updated on April 17, 2014 at 13:47 EDT

Latest Overactive bladder Stories

2012-05-17 02:25:19

MINNEAPOLIS, May 17, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ:UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that at the May 19-22, 2012 Annual Meeting of the American Urological Association (AUA) in Atlanta, GA, there will be two presentations on Uroplasty's Urgent® PC Neuromodulation System. "The presentations on Urgent PC scheduled for the AUA meeting will feature the...

2012-05-16 06:27:48

MINNEAPOLIS, May 16, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI) announced today that it will release financial results for the fourth quarter and full year of fiscal 2012 ended March 31, 2012, at the market close on Thursday, May 24, 2012. The Company will host a conference call to discuss these results on Thursday, May 24, 2012 at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). David Kaysen, President and Chief Executive Officer, and Medi Jiwani, Vice President, Chief...

2012-05-07 10:25:02

MINNEAPOLIS, May 7, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, announced today that David Kaysen, President and CEO, and Medi Jiwani, Vice President and CFO, will present the Company's business strategy and financial results at the 11th( )Annual JMP Securities Research Conference at 12:30 pm PT on Monday, May 14, 2012 at the Ritz-Carlton Hotel in...

2012-05-04 02:24:52

FRAZER, Pa., May 4, 2012 /PRNewswire/ -- Teva Women's Health today announced new data from the Company's expanding women's health franchise will be featured at the 60th Annual Clinical Meeting of the American Congress of Obstetricians and Gynecologists (ACOG) in San Diego, California, May 5-9, 2012. Featured presentations and abstracts will include new data on Plan B One-Step® (levonorgestrel) tablet 1.5mg, the only one pill emergency contraceptive available over-the-counter to women 17...

2012-04-26 10:25:37

MINNEAPOLIS, April 26, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that Novitas Solutions (formerly Highmark Medicare Services) on April 23, 2012 informed the Centers for Medicare and Medicaid Services that it has retired the non-coverage provisions concerning Posterior Tibial Nerve Stimulation (PTNS) from their Local...

2012-04-26 02:28:10

PARSIPPANY, N.J. and EWING, N.J., April 26, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) and Antares Pharma, Inc. (NYSE Amex: AIS) today announced the launch of Gelnique 3%(TM) (oxybutynin) gel 3%, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency. Gelnique 3%(TM) is a clear, odorless topical gel that has been shown to be an effective and safe treatment for OAB. The product is available in a metered pump...

2012-04-16 02:27:34

MINNEAPOLIS, April 16, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI) announced today that the United States Agency for Healthcare Research and Quality (AHRQ) in a recently issued document titled "Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness" included favorable statements on the safety and effectiveness of percutaneous tibial nerve stimulation (PTNS) for overactive bladder (OAB). Uroplasty's Urgent®( )PC Neuromodulation System...

2012-04-05 14:21:02

DEERFIELD, Ill., April 5, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that the Reproductive Health Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted that the overall risk/benefit assessment supports approval of mirabegron (YM178) for the treatment of overactive bladder (OAB) (Yes: 7, No: 4, Abstain: 1). Today's committee recommendation, although not binding, will...

2012-03-12 11:31:27

New treatment for overactive bladder is trialed by the University of Leicester The biggest study into the treatment of urinary incontinence with botulinum toxin (trade name Botox) has demonstrated that it is effective in treating overactive bladder (OAB) - a debilitating common condition which can affect up to 20% of people over the age of 40. The study from the University of Leicester was led by Dr. Douglas Tincello, Senior Lecturer at the University and Honorary Consultant...

2012-03-05 07:00:00

MINNEAPOLIS, March 5, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, announced today that David Kaysen, President and CEO, and Medi Jiwani, Vice President and CFO, will present the Company's business strategy and financial results at the 24th Annual ROTH Conference at 5:30 PM PT on Monday, March 12, 2012 at The Ritz Carlton Laguna Niguel in Dana Point,...